Luteolin offers novel therapeutic regimen in rotenone-induced Parkinson disease via modulation of TNF-α/FXMRP/serotonin/tyrosine hydroxylase signaling pathway. NJPS [інтернет]. 31, Грудень 2025 [цит. за 14, Квітень 2026];40(2):251-62. доступний у: https://www.ojshostng.com/index.php/njphysiologicalsciences/article/view/4001